Navigation Links
Breast cancer and heart disease may have common roots
Date:12/20/2011

TORONTO, ON., Dec. 20, 2011Women who are at risk for breast cancer may also be at greater risk for heart disease, new research has found.

The majority of women with hereditary breast and ovarian cancer have a mutated form of the BRCA1 or BRCA2 genes, which normally suppress the growth of breast and ovarian tumours.

Dr. Subodh Verma, a cardiac surgeon at St. Michael's Hospital, said his research team was surprised to discover the genes also regulate heart function.

Following a heart attack, mice with the mutated BRCA1 gene had a three-to-five times higher rate of death. This was largely due to the development of profound heart failure, possibly because their heart attacks were twice as severe as those in mice who did not have the mutated gene.

A similar two-fold increase in heart failure was observed when mice with a mutated BRCA1 or BRAC2 gene were treated with doxorubicin, one of the most common chemotherapy drugs for patients with breast cancer. In addition to studies in mice, the authors also verified this observation in human tissues.

The researchers believe that the mutated BRCA1/2 prevents DNA repair in muscle cells that is essential to recovery after a heart attack.

Their findings were published in the journals Nature Communications and Journal of Biological Chemistry.

"Our findings suggest that individuals who are at risk of breast cancer may also be at a previously unrecognized risk of heart disease," Dr. Verma said. "More importantly, we now understand that breast cancer and heart disease -- the two leading causes of death for Canadian women have a common biological basis, a common soil."

Dr. Verma emphasized that these findings may have important implications for patients. Knowing that the BRCA1/2 gene is essential to DNA repair may lead to future treatments for anyone with heart disease, a leading cause of death worldwide. Women who carry this mutated gene now know they may also be at a higher risk for developing heart disease in addition to the risk of developing cancer.

Dr. Christine Brezden-Masley, an oncologist at St. Michael's and a co-author of the paper, said that while physicians knew doxorubicin was associated with heart failure, the new research shows women with the mutated BRCA1/2 gene are particularly sensitive to its toxicity.

"What this means is that when a patient has the mutated gene, I now have to think about how much doxorubicin I'm going to give them or whether we should consider an alternate therapy," Dr. Brezden-Masley said.


'/>"/>

Contact: Leslie Shepherd
shepherdl@smh.ca
416-864-6094
St. Michael's Hospital
Source:Eurekalert

Related medicine news :

1. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
4. For Some Breast Cancer Patients, Shorter Radiation Works Well
5. Short-term radiation therapy successful on breast cancer
6. Few Women at High Risk for Breast Cancer Take Tamoxifen
7. Hormone May Prevent Aggressive Breast Cancer
8. MSU researcher linking breast cancer patients with alternative therapies
9. MRI May Not Add Value to Routine Breast Cancer Care
10. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
11. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 29, 2017 , ... The ... Dr. Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March 1, ... questions regarding thyroid function. , Dr. Izabella Wentz is a licensed pharmacist ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... services, is proud to announce it has joined the National Association for Home ... interests of chronically ill, disabled, and dying Americans of all ages and the ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Alert Sentry ... of MPERS (Mobile Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These ... market. The first of their kind, the iSAFE and iSAFE Plus offer direct GPS ...
(Date:3/28/2017)... ... March 28, 2017 , ... Usually, the impending arrival of ... However, for those self-conscious about a double chin, this means more anxiety than elation. ... , “For most people, a double chin is undesirable,” Dr. Goldman said, “but ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017 Elysium ... with Cambridge academic ...   The Milner Therapeutics Institute today announces Elysium ... Health has committed significant investment for collaborative projects with academic ... four years. This is the first major research investment outside ...
(Date:3/27/2017)... Summary This report provides all the ... partnering interests and activities since 2010. Description The Partnering ... into the partnering activity of one of the world,s leading ... prepared upon purchase to ensure inclusion of the most up ... will be delivered in PDF format within 1 working day ...
(Date:3/27/2017)...  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, ... and efficacy studies. The company is harnessing the power ... MAGE A, in an effort to find a better ... After 4 weeks of treatment in transgenic mice, the ... in a full toxicology report of various organs. Cytotoxic ...
Breaking Medicine Technology: